BSTC News Alert Biospecifics Technologies Corp (BSTC) 37.58 12/13/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biospecifics Technologies Corp (BSTC) 37.58 $BSTC

Insider Trading Alert - JBHT, BSTC And AAPL Traded By Insiders
at The Street - Wed Nov 26, 9:00AM CST
Stocks with insider trader activity include JBHT, BSTC and AAPL
BSTC: 37.58 (+0.38), JBHT: 82.16 (+1.64), AAPL: 109.73 (-1.89)

BioSpecifics Technologies Corp. Announces New Data on XIAFLEX® for Peyronie's Disease Presented at SMSNA Scientific Meeting
PR Newswire - Fri Nov 21, 7:30AM CST
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced new data on XIAFLEX for the treatment of Peyronie's disease from the Phase 2 and the pivotal Phase 3 IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, presented by BioSpecifics' licensee, Auxilium Pharmaceuticals, Inc. (Auxilium) at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA) held in Miami, FL from November 20-23, 2014.
BSTC: 37.58 (+0.38), AUXL: 33.11 (-0.72)

Update: BioSpecifics Technologies Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Fri Nov 21, 6:37AM CST

ENDP: 68.77 (-2.45), BSTC: 37.58 (+0.38), AUXL: 33.11 (-0.72)

BioSpecifics Technologies Corp. to Present at the Stifel 2014 Healthcare Conference
PR Newswire - Wed Nov 12, 3:01PM CST
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, announced today that BioSpecifics' President, Tom Wegman, will present a corporate overview at the Stifel 2014 Healthcare Conference.
BSTC: 37.58 (+0.38)

BioSpecifics Technologies (BSTC) Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 6:09PM CST

BSTC: 37.58 (+0.38)

BioSpecifics Tech beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:11AM CST

BSTC: 37.58 (+0.38)

BioSpecifics Technologies Corp. Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 10, 7:00AM CST
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the third quarter ended September 30, 2014 and provided a corporate update.
BSTC: 37.58 (+0.38)

BioSpecifics Tech reports November 10
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 12:11PM CST

BSTC: 37.58 (+0.38)

BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2014 Financial Results on Monday, November 10, 2014
PR Newswire - Mon Nov 03, 7:30AM CST
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, announced today that it will host a conference call and live audio webcast at 8:30 a.m. EST on Monday, November 10, 2014 to report its third quarter 2014 financial results and provide a corporate update.
BSTC: 37.58 (+0.38)

BioSpecifics Technologies Corp. Announces FDA Approval of sBLA for XIAFLEX® for the Concurrent Treatment of Two Dupuytren's Contracture Cords
PR Newswire - Tue Oct 21, 7:00AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) submitted by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium) for XIAFLEX for the treatment of up to two Dupuytren's contracture cords in the same hand during a single treatment visit. XIAFLEX obtained FDA approval in 2010 as the first and only nonsurgical treatment for adult Dupuytren's contracture patients with a palpable cord in the palm.
BSTC: 37.58 (+0.38)

BioSpecifics Technologies Corp. Announces Presentation of Encouraging Preclinical Data for CCH from Collaborative Uterine Fibroid Study with Duke Medicine
PR Newswire - Thu Oct 16, 7:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, announces that a paper titled, "Stiffness of Human Uterine Fibroids is Reduced After Treatment with Purified Clostridial Collagenase due to Collagen Degradation" was presented at the Mechanotransduction in the Reproductive Tract conference hosted by the Campion Fund of the Phyllis and Mark Leppert Foundation for Fertility Research in Durham, North Carolina. The data being presented show that highly purified collagenase can reduce the rigidity of human uterine fibroid tissue and potentially shrink uterine fibroid tumors by interrupting the accumulation of poorly aligned and altered collagen.
BSTC: 37.58 (+0.38)

BioSpecifics Technologies Corp. Announces Sudden Passing of Director Max Link, Ph.D.
PR Newswire - Wed Oct 08, 3:05PM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), today announced with great sadness that Max Link, Ph.D., a member of its Board of Directors, passed away unexpectedly on October 5, 2014. He was 74 years old. Dr. Link served as the Chair of the Compensation Committee, as the Audit Committee Financial Expert and as a member of the Board's Audit, Compensation and Nominating and Corporate Governance Committees.
BSTC: 37.58 (+0.38)

BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference
PR Newswire - Fri Sep 19, 7:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, announced today that BioSpecifics' President, Tom Wegman, will present a corporate overview at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference.
BSTC: 37.58 (+0.38)

BioSpecifics Technologies Corp. Announces New MULTICORD and Retreatment Data for XIAFLEX® for Dupuytren's Contracture Presented at American Society for Surgery of the Hand Annual Meeting
PR Newswire - Thu Sep 18, 3:17PM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced that positive safety and efficacy data from the MULTICORD (MULtiple Treatment Investigation of Collagenase Optimizing the Resolution of Dupuytren's) Phase 3b study will be presented by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium) at the 69th Annual Meeting of the American Society for Surgery of the Hand (ASSH) being held in Boston on September 18-20, 2014. Positive data were also presented from an additional study evaluating the retreatment of recurrent contracture in joints that were previously treated with CCH.
BSTC: 37.58 (+0.38)

BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
PR Newswire - Tue Sep 02, 7:00AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, announced today that BioSpecifics' President, Tom Wegman, will present at the following upcoming investor conferences.
BSTC: 37.58 (+0.38)

BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite
PR Newswire - Thu Aug 21, 4:36PM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced positive, statistically significant results from a randomized, double-blind Phase 2a study of CCH for the potential treatment of cellulite, or edematous fibrosclerotic panniculopathy. The results showed that all three doses of CCH used in the study, including a low, medium and high dose, demonstrated an improvement in the appearance of cellulite as measured by the trial endpoints of physician and patient-assessed improvements. CCH was well-tolerated by all dose groups with most adverse events being mild to moderate and primarily limited to the local injection area.
BSTC: 37.58 (+0.38)

BioSpecifics Technologies Corp. Reports Second Quarter 2014 Financial Results
PR Newswire - Mon Aug 11, 3:01PM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the second quarter ended June 30, 2014 and provided a corporate update.
BSTC: 37.58 (+0.38)

BioSpecifics Technologies Corp. Announces Initiation of Phase 2 Clinical Study of CCH for Treatment of Lipoma
PR Newswire - Fri Aug 08, 7:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, announced today that it has injected the first patient in its placebo-controlled Phase 2 clinical trial of CCH for the treatment of lipoma. The Company expects to complete patient enrollment in this trial during the first quarter of 2015.
BSTC: 37.58 (+0.38)

BioSpecifics Technologies Corp. Announces Appointment of Max Link, Ph.D. to Board of Directors
PR Newswire - Tue Aug 05, 7:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced the appointment of Max Link, Ph.D. to its Board of Directors, effective August 4, 2014, with a term of office expiring and to be renewed at the 2016 Annual Meeting of Stockholders. BioSpecifics also announced today that as of August 15, 2014, Henry G. Morgan will retire from the Board of Directors after 24 years of service but will continue to act in a consulting capacity.
BSTC: 37.58 (+0.38)

BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2014 Financial Results on Monday, August 11, 2014
PR Newswire - Mon Aug 04, 7:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, announced today that it will host a conference call and live audio webcast at 4:30 p.m. EDT on Monday, August 11, 2014 to report its second quarter 2014 financial results and provide a corporate update.
BSTC: 37.58 (+0.38)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 35

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Flexible Packaging Market to Hit $384.32B by 2031

Updated Category News Views 22

Packaging's Flexible Future Alright, here's the skinny: you might want to adjust those portfolios if you're watching the materials sector, because the flexible packaging market ain't just loosening up—it's stretching out like never before. By 2031, we're talking about it raking in a solid $384.32 billion, climbing from $313.25 billion in 2026. That's a not-so-shabby...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 152

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
Tammy Keller's Devotional Guides Living with Purpose

Updated Category News Views 77

Finding Meaning in the Dash of Life Life isn’t just bookended by birth and death; it’s the dash in between that counts. If you were sitting next to Tammy Keller right now, you’d probably hear that heartfelt truth straight from her. Her new work, "Your--Dash Devotional," rattles the soul by offering a profound look at making every moment intentional, vivid, and...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 223

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 126

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 145

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 51

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 5

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
NVIDIA Faces Fraud Suit: Investors Called to Action

Updated Category News Views 18

NVIDIA and the Quest for Accountability Nothing screams chaos in the market louder than a securities fraud lawsuit hitting the headlines. Investors currently eyeballing NVIDIA Corporation (NASDAQ: NVDA) are in for a wild ride. Yep, you heard it right—NVIDIA is smack in the middle of a class action lawsuit. They're being accused of misleading the market about some shady...

Continue Reading

Top 5 Most Recently Viewed Articles

Aircraft Rescue and Firefighting Vehicles Market Growth

Updated Category News Views 218

Overview of the Global Aircraft Rescue and Firefighting Vehicles Market The Global Aircraft Rescue and Firefighting Vehicles Market is on track for substantial growth, with projections indicating an increase from USD 51.2 billion in 2023 to USD 79.9 billion by 2033. This growth equates to a Compound Annual Growth Rate (CAGR) of 4.55% during the forecast period. The rise...

Continue Reading
Shifting Driver Attitudes: Rudeness on the Rise in PNW

Updated Category News Views 314

Driving Rudeness in the Pacific Northwest: A Growing Concern In recent times, there has been a noticeable increase in rudeness among drivers on the roads of the Pacific Northwest. A poll by PEMCO indicates that many residents in the region feel this shift in behavior is very real. Many drivers, approximately 73%, believe that traffic violations are on the rise, with...

Continue Reading
Beeline Transforming Mortgage Services with AI Agent Bob

Updated Category News Views 175

Beeline Holdings Makes AI Move with Agent Bob Beeline Holdings, known for its innovative approach in the mortgage industry, has embarked on an exciting transformation with its proprietary AI agent, Bob. Initially developed for customer support, Bob is venturing into direct sales and origination activities, marking a pivotal shift in how the company operates. Leading the...

Continue Reading
Simplilearn Unveils Alby AI to Redefine Upskilling

Updated Category News Views 27

An Era of Tailored Education Kicks Off How many times have we heard about some 'revolutionary' AI hitting industries like a bull in a china shop, only to fizzle out when reality sets in? Well, hang on to your hats because Simplilearn's latest move is cooking up something genuinely spicy in the education sector. They've just launched Alby AI, claimed to be the world's...

Continue Reading
Faraday Future Launches Faraday X Brand with New EV Models

Updated Category News Views 188

Faraday Future Unveils Faraday X Brand and Innovative Electric Vehicles Faraday Future Intelligent Electric Inc. (Nasdaq: FFIE) has recently embarked on a thrilling new journey by launching its second brand, Faraday X (FX). This move is part of a strategic plan to create a comprehensive intelligent electric mobility ecosystem. With the introduction of FX, Faraday Future...

Continue Reading